What type of merger is Sun Pharma and Ranbaxy?
Sun Pharmaceutical Industries Ltd is buying Ranbaxy Laboratories Ltd through an all-stock merger in which five shares of Ranbaxy will fetch four shares of Sun Pharma.
Why did Sun Pharma and Ranbaxy merger?
“The merger creates a combined entity which has managerial capability that is significantly greater than either company alone,” said Shanghvi. Sun Pharma agreed to acquire Ranbaxy from Japan’s Daiichi Sankyo Co. Ltd for $3.2 billion in stock in addition to assuming $800 million of debt.
Which company merged with Sun Pharma?
Ranbaxy
In one stroke Sun Pharmaceuticals has doubled its size in a cashless transaction by acquiring one of India’s largest pharmaceutical company – Ranbaxy.
What is the intrinsic value of Sun Pharma?
Sun Pharmaceuticals
| As Of | Intrinsic Value | Market Price |
|---|---|---|
| 31 Mar 2022 | Rs. 309.27 | Rs. 914.75 |
| 27 Jun 2022 | —- | Rs. 835.65 |
| 11.05 1.32% |
What is it called when Sun Pharmaceutical Industries Ltd merged with Ranbaxy Laboratories Ltd?
Sun Pharma completed the acquisition of Ranbaxy Laboratories Limited, an integrated, research based, international pharmaceutical company, on 25th March 2015.
What’s it called when a company buys another company?
The terms “mergers” and “acquisitions” are often used interchangeably, but they differ in meaning. In an acquisition, one company purchases another outright. A merger is the combination of two firms, which subsequently form a new legal entity under the banner of one corporate name.
When did Sunpharma acquire Ranbaxy?
When did Sun Pharma merger with Ranbaxy?
Who owns Ranbaxy and Sun Pharma companies?
In 2008, Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in Ranbaxy and in 2014, Sun Pharma acquired 100% of Ranbaxy in an all-stock deal….Ranbaxy Laboratories.
| Trade name | Ranbaxy headquarters in Gurgaon, Haryana, India |
|---|---|
| Number of employees | 10,983 (2012) |
| Parent | Sun Pharmaceuticals |
Is SUNPHARMA undervalued?
SUNPHARMA is one of the potential top 21% undervalued companies !
What is the future of SUNPHARMA?
The higher strength in a market that normally grows at 10 per cent, is expected to translate into even higher growth for Sun Pharma which focusses on product launches (28 launched in Q2FY22 alone) and in-licensing opportunities. Sun Pharma reported sales growth of 2.5 per cent in FY21 of ₹33,139 crore.
What do you know about Sun Pharma?
From humble beginnings in 1983, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. We are the largest pharmaceutical company in India. In the US, we are among the top 10 generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market.
What went wrong with Ranbaxy?
It was accused of falsifying data and test results in pending and approved applications. Later, the USFDA banned more than two dozen Ranbaxy drugs from entering the country. Ranbaxy had to pay $500 million in fines and restitution to US authorities as part of a settlement.
Should I invest in SUNPHARMA?
Sun Pharma stock has rewarded investors with a 47.1 percent return in the past one year, exceeding the Nifty50’s 23.1 percent rise by a wide margin. The brokerage retained its ‘buy’ rating on the Sun Pharma stock with a target price of Rs 1,070.
What does Sun Pharma-Ranbaxy merger mean for Ranbaxy?
The shareholders of Ranbaxy would receive a 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represented an implied value of Rs.457 for each Ranbaxy share. The combination of Sun Pharma and Ranbaxy was expected to create the fifth largest generic drug making company in the world and the largest in India.
What is the value of Ranbaxy shares?
The transaction had a total equity value of approximately US$ 3.2 billion , . The shareholders of Ranbaxy would receive a 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represented an implied value of Rs.457 for each Ranbaxy share.
What happened to Ranbaxy Company Limited?
Ranbaxy B.V., Netherlands, a 100% subsidiary of Ranbaxy also became a subsidiary of Sun Pharma. Series of deals by Sun pharma is enlisted in Table 3. Shares of Ranbaxy Company Limited stopped trading on 6 th April, 2014. The deal materialized
What are the terms of Sun Pharmaceuticals-Ranbaxy deal?
Under terms of the agreed deal, Ranbaxy shareholders will get 0.8 of a Sun Pharmaceutical share for each Ranbaxy share they own. Daiichi Sankyo said in a statement that it will hold a stake of about 9 per cent in Sun Pharmaceutical after the deal.